The pulmonary delivery of antibiotics is a pivotal approach in treating respiratory infections,
enabling targeted drug administration while minimizing systemic side effects. In recent …

Pulmonary infections may be fatal especially in immunocompromised patients and patients
with underlying pulmonary dysfunction, such as those with cystic fibrosis, chronic obstructive …

As the WHO stated, lower respiratory infections are the third leading cause of death. In
addition, it is remarkable that antimicrobial resistance represents a huge threat. Thus, new …

A boom in respiratory tract infection cases has inflicted a socio-economic burden on the
healthcare system worldwide, especially in developing countries. Limited alternative …

Recalcitrant respiratory tract infections caused by bacteria have emerged as one of the
greatest health challenges worldwide. Aerosolized antimicrobial therapy is becoming …

Over the past decades, research on nanomedicines as innovative tools in combating
complex pathologies has increased tenfold, spanning fields from infectiology and …

Bacterial pneumonia is one of the leading causes of death worldwide and exerts a
significant burden on health-care resources. Antibiotics have long been used as first-line …

Cystic fibrosis (CF), a genetic lethal chronic disease, causes the body to produce abnormally
thick and sticky mucus. As a consequence following bacterial infections threaten ten …

Respiratory tract infections are one of the most frequent infections worldwide, with an
increasing number being associated with (multiple) antibiotic-resistant pathogens. Improved …

Introduction: Nanoparticles are under discussion in drug delivery for more than 20 years
now, but examples for nanoparticulate formulations in the treatment of respiratory diseases …